Treatment of complicated urinary tract infection in adults: Combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue SUPPL. 2, 2004, Pages

  Wells, Wilbur G ^a   Woods, Gail L ^b,c   Jiang, Qi ^b,d   Gesser, Richard M ^b   Albertson, Elizabeth A ^e   Al Ibrahim, Mohamed S ^e   Burdman, Emmanuel A ^e   Burke, Thomas F ^e   Childs, Stacy ^e   Cox, Clair ^e   Eng, Robert H K ^e   Frank, Elliot ^e   Brooks Gainer II, Robert ^e   Gonzalez Fuenzalida, Fernando ^e   Gezon, John A ^e   Herman, Theodore ^e   Jacoby, Karny ^e   Krinsky, Andrew H ^e   Landau, Richard E ^e   Moseley, William ^e   Rangel Frausto, M Sigfrido ^e   Recinos Mijangos, Gilbert ^e   Reinchardt, John F ^e   Pamo Reyna, Oscar G ^e   Sarshik, Stuart ^e   Schilling, Albretch ^e   Tomera, Kevin M ^e   Walzer, Yair ^e   Tuttle Jr , John ^e   Wells, Glen ^e   Amenabar, Alfredo ^e   Baird, Ian ^e   Bauwens, J Eric ^e   Bergen, Gary ^e   Brownstone, Paul ^e   Cajigas, Jaime ^e   Coto, Daniel ^e   Fierer, Joshua ^e   Flores, Nicolas ^e   Gallego Gomez, Juan ^e   Gatien, Lionel ^e   Gilbert, David ^e   Jasovich, Abel ^e   Jimenez Cruz, Fernando ^e   Keiller, Danny ^e   Khardori, Nancy ^e   Kreder, Karl ^e   Mansa Pueyo, Jose ^e   Marberger, Michael ^e   Mirelman, Simon ^e   Pryluka, Daniel ^e   Rauchenwald, Michael ^e   Rikhotso, Lybon T ^e   Tallada Bunnuel, Miguel ^e   Weems, Williams ^e   Wegenke, John ^e   more..

^a Alabama Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ARUP LABORATORIES   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Merck and Co Inc ^*

Author keywords

Acute pyelonephritis; Antimicrobial agents; Carbapenems; Efficacy; Safety

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; HEADACHE; HUMAN; KLEBSIELLA PNEUMONIAE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE CULTURE; VAGINITIS; VEIN DISEASE; ACUTE PYELONEPHRITIS; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM DETECTION; BACTERIUM ISOLATION; DISEASE ASSOCIATION; DRUG INFUSION; DRUG SUBSTITUTION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HUMANS; LACTAMS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 3042546497     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh208     Document Type: Article

References (26)

1. Foxman, B., Barlow, R., D'Arcy, H. et al. (2000). Urinary tract infection: self-reported incidence and associated costs. Annals of Epidemiology 10, 509-15.
2. Warren, J. W., Abrutyn, E., Hebel, J. R. et al. (1999). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clinical Infectious Diseases 29, 745-58.
3. Rubin, R. H., Shapiro, E. D., Andriole, V. T. et al. (1992). Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clinical Infectious Diseases 15, Suppl. 1, 216-27.
4. Cox, C. E. (1989). Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. American Journal of Medicine 87, Suppl. 5A, 157S-59S.
5. Shah, P. M. & Isaacs, R. D. (2003). Ertapenem, the first of a new group of carbapenems. Journal of Antimicrobial Chemotherapy 52, 538-42.
6. Livermore, D. M., Carter, M. W., Bagel, S. et al. (2001). In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrobial Agents and Chemotherapy 45, 1860-7.
7. Fuchs, P. C., Barry, A. L. & Brown, S. D. (2001). In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrobial Agents and Chemotherapy 45, 1915-8.
8. Majumdar, A., Musson, D., Birk, K. et al. (2002). Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrobial Agents and Chemotherapy 46, 3506-11.
9. Friedland, I., Mixson, L. A., Majumdar, A. et al. (2002). In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. Journal of Chemotherapy 14, 483-91.
10. Jimenez-Cruz, F., Jasovich, A., Cajigas, J. et al. (2002). A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Urology 60, 16-22.
11. Tomera, K., Burdmann, E., Pamo, O. et al. (2002). Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective randomized, double-blind multicenter study. Antimicrobial Agents and Chemotherapy 46, 2895-900.
12. National Committee for Clinical Laboratory Standards. (1997). Performance Standard for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A6. NCCLS, Villanova, PA, USA.
13. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA.
14. Cochran, W. G. (1954). Some methods for strengthening the common chi-square tests. Biometrics 10, 417-51.
15. Klimberg, I. W., Cox, C. E., 2nd, Fowler, C. L. et al. (1998). A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 51, 610-5.
16. Nicolle, L. E., Louie, T. J., Dubois, J. et al. (1994). Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy 38, 1368-73.
17. Naber, K. G., Silverio, F. D., Geddes, A. et al. (1996). Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 135-44.
18. Raz, R., Chazan, B., Kennes, Y. et al. (2002). Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clinical Infectious Diseases 34, 1165-9.
19. Gupta, K., Scholes, D. & Stamm, W. E. (1999). Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. Journal of the American Medical Association 281, 736-9.
20. Jones, R. N., Kugler, K. C., Pfaller, M. A. et al, (1999). Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagnostic Microbiology and Infectious Disease 35, 55-63.
21. Friedland, I., Isaacs, R., Mixson, L. et al. (2002). Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagnostic Microbiology and Infectious Disease 43, 61-4.
22. Ortiz-Ruiz, G., Caballero-Lopez, J., Friedland, I. et al. (2002). A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clinical Infectious Diseases 34, 1076-83.
23. Vetter, N., Cambronero-Hernandez, E., Rohlf, J. et al. (2002). A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clinical Therapeutics 24, 1770-85.
24. Solomkin, J. S., Yellin, A. E., Rotstein, O. D. et al. (2003). Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Annals of Surgery 237, 235-45.
25. Graham, D., Lucasti, C., Malafaia, O. et al. (2002). Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Diseases 34, 1460-8.
26. Roy, S., Higareda, I., Angel-Muller, E. et al. (2003). Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infectious Diseases in Obstetrics and Gynecology 11, 27-37.